Evaluation Of Short-term Curative Effect Of Apatinib Mesylate On Recurrent Epithelial Ovarian Cancer

Objective:The purpose of this study was to analyze the efficacy and safety of apatinib mesylate(Itan)in the treatment of recurrent ovarian cancer.Methods:This study retrospectively analyzed the medical records of 62 patients with recurrent epithelial ovarian cancer admitted to the gynecological chronic hospital of the First Affiliated Hospital of China Medical University from September 2016 to September 2017.According to the treatment methods,62 patients were divided into 2teams.In the Eitan group,the treatment dose was 500 mg/d for a treatment period of 3months;the non-Itantan group was 45 patients,20 of which were given Etoposide 25mg/m~2 21d orally,and 8 patients were given paclitaxel 80 mg/m~2After treatment with 1.5mg/m~2of tutocan,6 patients received weekly treatment with atortetide 4 mg/m~2,6patients received docetaxel 40 mg/m~2 weekly treatment,and 5 patients received gemcitabine plus oxaliplatin dose.Saliplatin was administered on the first day at 130mg/m~2;gemcitabine was administered at 1,000 mg/m~2on the first and eighth days).All patients were followed for 3 months and evaluated according to RECIST1.1 criteria.NCI-CTCAE version 3.0 graded adverse drug reactions.Results:All 62 patients survived until the end of follow-up.There were 8 PR cases(47.06%),5 SD cases(29.41%),and 4 PD cases(23.53%)in the Eitan group.In the non-Itantan group,12 cases(26.67%)of PR,13 cases of SD(28.89%),and 22 cases of PD(48.89%)occurred.The ORR and DCR of the Eitan group were 47.06%and 76.47%,respectively.The ORR and DCR of the non-Itantan group were 26.67%and 55.56%,respectively.There was a statistical difference between the two groups(p<0.05).There were 2 cases(11.76%),3 cases(17.65%),1 case(5.88%),and 1 case of hand-foot syndrome,hypertension,gastrointestinal adverse reactions,hematologic toxicity and proteinuria events in grade III or above in the Eitan group.(5.88%)and 3 cases(17.65%),no grade 3 or more abnormal liver and kidney function occurred.There were 3 cases(6.67%),3 cases(6.67%)and 5 cases(11.11%)of hand-foot syndrome,gastrointestinal adverse reactions and hematologic toxicities in Grade III or higher in non-Aiitan group,no Grade 3 or higher hypertension,Abnormal liver and kidney function and proteinuria events.The incidence of grade III hypertension and proteinuria in the Eitan group was higher than that in the non-AItan group,and the incidence was statistically different(p<0.05).Conclusion:1.Compared with second-line chemotherapy drugs,apatinib mesylate has certain advantages in relieving clinical symptoms and controlling the progression of recurrent ovarian cancer.2.Compared with the second-line chemotherapeutics,apatinib mesylate had no significant difference in liver function abnormalities and adverse reactions of the digestive system above grade III,but it needs further attention in terms of hypertension and proteinuria adverse reactions.